Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180 18 November 2026 BLS Provides Update on UK Manufacturing • Construction and ?tout completed at BLS's pharmaceutical manufacturing facility in the Scottish Borders, UK • UK Home Of?ce...
BLS Provides Update on UK Manufacturing
Filed with ASX · · 3 pages · English
Summary by 6ix AI
BLS Pharmaceuticals Limited provides an update on its UK manufacturing facility, reporting that construction and fitout have been completed in the Scottish Borders, UK. The UK Home Office inspection has commenced as part of the facility's licensing process, with further regulatory audits ongoing. Once licensed, the facility aims to support local pharmaceutical manufacturing and expand BLS's capabilities in the UK and European medicinal cannabis markets. The company anticipates that the facility will significantly enhance its revenue growth capacity.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
BLS Pharmaceuticals Limited on 6ix
In the deck
Earlier from BLS Pharmaceuticals
- Application for quotation of securities - BLS
- To Present at Bell Potter Health Care Conference 19.11.2026
- Directors Change of Interest Notice X 2
- Letter to Shareholders re Annual General Meeting
- Notice of Annual General Meeting/Proxy Form
Later from BLS Pharmaceuticals
All BLS Pharmaceuticals news releasesFollow BLS Pharmaceuticals into a list and get an email when it puts out news.
Follow BLS Pharmaceuticals